A Phase 4 interventional study of Danshen Dripping Pill and Placebo in Diabetic Microvascular Angina, sponsored by Qilu Hospital of Shandong University. Not yet recruiting at 3 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-11.
Sponsored by Qilu Hospital of Shandong University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Microvascular Angina with a site in China — 9 open to participants now, 9 under way, none of them phase 3. Microvascular Angina · China.
Among the 15 studies in Microvascular Angina with a site in China, this one is the 7th largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2025, is one of 7 in phase 4, and was the 12th registered.
111 studies on the registry are indexed under Microvascular Angina; 38 are open to participants now.
Browse Microvascular Angina studies →9 of the 15 studies in Microvascular Angina with a site in China are open now. Recruiting first, the newest first:
Qilu Hospital of Shandong University · Sites in China
Ages 18–80
Henan Institute of Cardiovascular Epidemiology · Sites in China
Ages 18–85
China-Japan Friendship Hospital · Sites in China
Ages 18–75
Qilu Hospital of Shandong University · Sites in China
Ages 40–75
The Affiliated Hospital of Xuzhou Medical University · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 27 Microvascular Angina studies recruiting now, 17 (63%) set no upper age limit and 3 (11%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1 · Phase 4 7
First in 2015; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 162 is above the median of 79 across 63 interventional studies indexed under Microvascular Angina.
Median enrollment 220 across the 10 interventional studies, 335 across the 5 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 15 have an industry lead sponsor. The 10 most frequent:
Qilu Hospital of Shandong University is the lead sponsor of 311 studies on the registry; 188 are open to participants now.
Qilu Hospital of Shandong University has 6 studies filed under Microvascular Angina — fewer than ten, so there is no comparison to draw.
2 of the studies in Microvascular Angina with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06727890Qilu Hospital of Shandong UniversityCompound Danshen Dripping Pill for Diabetic Microvascular Angina | 2026-12-31 |
| NCT06092736Qilu Hospital of Shandong UniversityMicrovascular Angina Intervention With Compound Danshen Dripping Pill (MAIDS) | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies in Microvascular Angina with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To investigate the efficacy and safety of Compound Danshen Dripping Pill in patients with diabetic microvascular angina pectoris. Long-term follow-up of 1 year will be performed to evaluate the effect of Compound Danshen Dripping Pill on coronary flow reserve and adverse cardiovascular events in patients with coronary microvascular disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
History of type 2 diabetes ≧5 years; Repeated chest pain attacks with typical exertional angina pectoris or resting angina pectoris attacks; Coronary normal or stenosis \<50%; Ischemic depression in ST segment during resting or exercise; Coronary flow reserve (CFR) of the anterior descending coronary artery \< 2.0, or CFR ≧2.0 but acetylcholine activation test is positive; Subjects or their guardians agreed to participate in this study.
Exclusion Criteria:
Previous myocardial infarction or PCI or CABG treatment; Severe arrhythmia; hypertension or hypertension accompanied by left ventricular wall thickness > 12 mm; Familial hypercholesterolemia; Takayasu arteritis, Kawasaki disease or coronary artery malformation; Pregnant or nursing, or having the intention to give birth within one year; Hepatic or renal dysfunction; Allergic to contrast agents or traditional Chinese medicines; Patients who participated in clinical research of other drugs within 3 months before being selected.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Danshen Dripping Pill
Drug: Placebo
Danshen Dripping Pill, 10 pills once, three times a day
Placebo, 10 pills once, three times a day
Changes of coronary flow reserve measured by three-dimensional echocardiography from baseline to 12 months after follow-up
Time frame: From baseline to the end of 12-month treatment
Plan to share: Undecided — It might damage the privacy of patients.
No publications or documents are linked to this record.
Start is estimated for Jan 2025; primary completion for Dec 2026, 23 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Qilu Hospital of Shandong University →